Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab-Reference-Cited by-同舟云学术

Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab

Published:2019-05 Issue:4 Volume:42 Page:136-141
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Afzal Muhammad Z.,Shirai Keisuke

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference30 articles.

1. First oncolytic viral therapy for melanoma;Poh;Cancer Discov,2016

2. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma;Andtbacka;J Clin Oncol,2015

3. Patterns of clinical response with Talimogene Laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial;Andtbacka;Ann Surg Oncol,2016

4. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry;Akhtar;FEBS J,2009

5. Molecular pathways: mechanism of action for Talimogene Laherparepvec, a new oncolytic virus immunotherapy;Kohlhapp;Clin Cancer Res,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modern approaches to treating cancer with oncolytic viruses;Microbiology Independent Research Journal (MIR Journal);2022-10-28

2. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier;Cancer Cell International;2022-01-03

3. Современные подходы к лечению рака онколитическими вирусами;Microbiology Independent Research Journal (MIR Journal);2022

4. Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma;Expert Opinion on Biological Therapy;2021-10-31

5. Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany;Journal for ImmunoTherapy of Cancer;2021-02